全文获取类型
收费全文 | 4703篇 |
免费 | 364篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 171篇 |
妇产科学 | 101篇 |
基础医学 | 588篇 |
口腔科学 | 116篇 |
临床医学 | 601篇 |
内科学 | 942篇 |
皮肤病学 | 49篇 |
神经病学 | 473篇 |
特种医学 | 364篇 |
外科学 | 566篇 |
综合类 | 96篇 |
一般理论 | 1篇 |
预防医学 | 364篇 |
眼科学 | 78篇 |
药学 | 333篇 |
中国医学 | 18篇 |
肿瘤学 | 208篇 |
出版年
2023年 | 18篇 |
2022年 | 28篇 |
2021年 | 55篇 |
2020年 | 34篇 |
2019年 | 60篇 |
2018年 | 77篇 |
2017年 | 47篇 |
2016年 | 67篇 |
2015年 | 75篇 |
2014年 | 127篇 |
2013年 | 156篇 |
2012年 | 226篇 |
2011年 | 218篇 |
2010年 | 150篇 |
2009年 | 120篇 |
2008年 | 221篇 |
2007年 | 222篇 |
2006年 | 216篇 |
2005年 | 190篇 |
2004年 | 184篇 |
2003年 | 204篇 |
2002年 | 188篇 |
2001年 | 173篇 |
2000年 | 165篇 |
1999年 | 129篇 |
1998年 | 98篇 |
1997年 | 105篇 |
1996年 | 111篇 |
1995年 | 77篇 |
1994年 | 58篇 |
1993年 | 75篇 |
1992年 | 89篇 |
1991年 | 86篇 |
1990年 | 105篇 |
1989年 | 120篇 |
1988年 | 109篇 |
1987年 | 94篇 |
1986年 | 95篇 |
1985年 | 85篇 |
1984年 | 44篇 |
1983年 | 48篇 |
1982年 | 23篇 |
1981年 | 33篇 |
1980年 | 27篇 |
1979年 | 30篇 |
1978年 | 27篇 |
1977年 | 23篇 |
1976年 | 32篇 |
1975年 | 19篇 |
1973年 | 23篇 |
排序方式: 共有5101条查询结果,搜索用时 0 毫秒
101.
102.
103.
Oral Diseases (2012) 19 , 46–58 Sjögren’s syndrome (SjS) is one of the most common autoimmune rheumatic diseases, clinically characterized by xerostomia and keratoconjunctivitis sicca. We investigated the following controversial topics: (i) Do we have reliable ways of assessing saliva production? (ii) How important are the quantity and quality of saliva? (iii) Are only anti‐SSA/Ro and anti‐SSB/La relevant for the diagnosis of SjS? (iv) Are the American‐European Consensus criteria (AECC) the best way to diagnose SjS? Results from literature searches suggested the following: (i) Despite the fact that numerous tests are available to assess salivation rates, direct comparisons among them are scarce with little evidence to suggest one best test. (ii) Recent developments highlight the importance of investigating the composition of saliva. However, more research is needed to standardize the methods of analysis and collection and refine the quality of the accumulating data. (iii) In addition to anti‐Ro/La autoantibodies, anti α‐fodrin IgA and anti‐MR3 autoantibodies seem to be promising diagnostic markers of SjS, but more studies are warranted to test their sensitivity and specificity. (iv) AECC are classification, not diagnostic criteria. Moreover, recent innovations have not been incorporated into these criteria. Consequently, treatment directed to patients diagnosed using the AECC might exclude a significant proportion of patients with SjS. 相似文献
104.
105.
J Tang DJ Humes E Gemmil NT Welch SL Parsons JA Catton 《Annals of the Royal College of Surgeons of England》2013,95(5):323-328
Introduction
The high mortality and morbidity associated with resection for oesophagogastric malignancy has resulted in a conservative approach to the postoperative management of this patient group. In August 2009 we introduced an enhanced recovery after surgery (ERAS) pathway tailored to patients undergoing resection for oesophagogastric malignancy. We aimed to assess the impact of this change in practice on standard clinical outcomes.Methods
Two cohorts were studied of patients undergoing resection for oesophagogastric malignancy before (August 2008 – July 2009) and after (August 2009 – July 2010) the implementation of the ERAS pathway. Data were collected on demographics, interventions, length of stay, morbidity and in-hospital mortality.Results
There were 53 and 55 oesophagogastric resections undertaken respectively for malignant disease in each of the study periods. The median length of stay for both gastric and oesophageal resection decreased from 15 to 11 days (Mann– Whitney U, p<0.001) following implementation of the ERAS pathway. There was no significant increase in morbidity (gastric resection 23.1% vs 5.3% and oesophageal resection 25.9% vs 16.7%) or mortality (gastric resection no deaths and oesophageal resection 1.8% vs 3.6%) associated with the changes. There was a significant decrease in the number of oral contrast studies used following oesophageal resection, with a reduction from 21 (77.8%) in 2008–2009 to 6 (16.7%) in 2009–2010 (chi-squared test, p<0.0001).Conclusions
The introduction of an enhanced recovery programme following oesophagogastric surgery resulted in a significant decrease in length of median patient stay in hospital without a significant increase in associated morbidity and mortality. 相似文献106.
107.
108.
Emma J. McMahon Judith D. Bauer Carmel M. Hawley Nicole M. Isbel Michael Stowasser David W. Johnson Katrina L. Campbell 《Journal of the American Society of Nephrology : JASN》2013,24(12):2096-2103
There is a paucity of quality evidence regarding the effects of sodium restriction in patients with CKD, particularly in patients with pre-end stage CKD, where controlling modifiable risk factors may be especially important for delaying CKD progression and cardiovascular events. We conducted a double-blind placebo-controlled randomized crossover trial assessing the effects of high versus low sodium intake on ambulatory BP, 24-hour protein and albumin excretion, fluid status (body composition monitor), renin and aldosterone levels, and arterial stiffness (pulse wave velocity and augmentation index) in 20 adult patients with hypertensive stage 3–4 CKD as phase 1 of the LowSALT CKD study. Overall, salt restriction resulted in statistically significant and clinically important reductions in BP (mean reduction of systolic/diastolic BP, 10/4 mm Hg; 95% confidence interval, 5 to 15 /1 to 6 mm Hg), extracellular fluid volume, albuminuria, and proteinuria in patients with moderate-to-severe CKD. The magnitude of change was more pronounced than the magnitude reported in patients without CKD, suggesting that patients with CKD are particularly salt sensitive. Although studies with longer intervention times and larger sample sizes are needed to confirm these benefits, this study indicates that sodium restriction should be emphasized in the management of patients with CKD as a means to reduce cardiovascular risk and risk for CKD progression.Cardiovascular disease (CVD) is the leading cause of premature mortality in the CKD population.1,2 CVD risk increases with only mild kidney impairment (estimated GFR [eGFR] <60 ml/min per 1.73 m2) and further escalates as CKD progresses,3 making early intervention to reduce CVD risk of utmost importance.4Dietary sodium intake shows great promise as a modifiable risk factor for reducing the risks of cardiovascular disease and CKD progression.5,6 Extensive research has demonstrated the effect of sodium intake on fluid overload and hypertension,7,8 which are predictors of cardiac and vascular remodeling.9 Trials in sodium restriction recently showed significant reductions in proteinuria and albuminuria,7,10,11 which are strong predictors of CKD progression and CVD events.12 In addition, excessive sodium intake is thought to have direct toxic effects on blood vessels through mediating factors such as oxidative stress, inflammation, endothelial cell dysfunction, and vascular stiffness.13–15The available evidence detailing the effects of sodium restriction in CKD patients is of poor quality, lacks randomization,16–18 a control group,17 or blinding,10,11 or does not use gold-standard measurement techniques (e.g., using clinic instead of ambulatory BP).10,11 Furthermore, several studies failed to either evaluate or adjust for the influence of key confounding factors, such as potassium intake or body weight,10,11,19–22 thereby making it difficult to assess whether the observed results can be solely attributed to dietary sodium.The aim of this double-blind placebo-controlled randomized crossover study was to evaluate the effects of dietary sodium intake on BP, proteinuria, extracellular fluid volume, and arterial stiffness as markers of risks of cardiovascular and CKD progression. We hypothesized that a low sodium intake would decrease 24-hour BP, fluid volume, and 24-hour urinary protein and albumin compared with high sodium intake in patients with moderate-to-severe CKD. 相似文献
109.
110.